The “Wegovy” brand slimming syringe is sold at the Achat pharmacy in Mitte. The slimming syringe “Wogovy” has been available in Germany for a year.
Jens Kalaene | Image Alliance | Getty images
CVS health On Thursday, he said that he will significantly expand access to the blockbuster weight loss stain for patients covered by its pharmacy benefits manager, CaMark.
As of July 1, Caremark will prioritize Wagovy in its forms, or lists of covered drugs, which makes it the preferred LPG-1 medicine for obesity. The measure is part of a new association between Caremark and the Wegovy manufacturer, Novo NordiskAccording to the release of the first quarter of CVS.
Caremark will also drop the medication to lose weight Zepbound from its standard forms on that date, in a blow to its manufacturer, Eli LillyA CVS spokesman told CNBC. They said that these standard forms are the most common between the Caremark client base, which represent dozens of millions of patients.
Eligible patients covered by Caremark who are currently taking Zepbound can change to Wegovy, said the spokesman.
Novo Nordisk's shares closed around 1% lower on Thursday, while Eli Lilly's shares closed more than 11% lower.
It occurs when Novo Nordisk works to increase access to Wagovy now that it is no longer scarce in the United States Association with Caremark, one of the largest pharmacy benefits managers in the country, could help the manufacturer of medicines to reach even more patients.
Caremark discounts medications with manufacturers on behalf of insurance plans and create drug lists, or forms, which are covered by safe and reimburse pharmacies for recipes.
Carekark will make its members available to its members at “a more affordable price.” The PBM negotiated a lower net price for Wogovy on Zepbound in its standard forms, offering savings to customers who opt for those plans, said the CVS spokesman.
But Caremark's customers, who are employers and unions, “determine individually how much of these savings in Wegovy are shared with their members through lower premiums or lower co -payments at the pharmacy counter,” said the spokesman.
Separately, any patient who does not have insurance coverage for Wegovy or other LPG-1 can still buy the pocket Novo Nordisk medication for $ 499 in any of the 9,000 CVS pharmacies throughout the country, the spokesman added.
In its gains launch, CVS said it is the first retail pharmacy that is associated with the new direct online pharmacy to the Consumer of Novo Nordisk, Novocare, to dispense patients with recipes. Novocare offers Wagovy at that lower price to patients who pay effective, who may have difficulty assuming the list price of approximately $ 1,000 of the medication before insurance and other reimbursements.
Caremark will also combine Wogovy with additional lifestyle support, such as personalized nutrition plans, as part of the CVS weight control program.
The announcement occurs when the Danish drug manufacturer is aimed at capturing more patients now than many composite pharmacies are legally restricted from making cheaper and not approved versions of Wogovy, with rare exceptions.
“It is unknown at this point how the migration of pharmacies composed of other pharmacy environments will occur,” CVS Health Group president, Prem Shah, said on Thursday. “But we hope that obviously there is some benefit when opening 9,000 stores, or 9,000 opportunities for patients to obtain the medication.”
Dave Moore, the Executive Vice President of Operations of the United States of Novo Nordisk, said in a separate statement on Thursday that “it is our responsibility to continue working with others throughout the United States health system to find innovative opportunities to meet the needs of these patients and connect them with authentic and approved by the FDA … in a convenient and affordable way.”
